Skip to content

The curative effective research of Chinese herbal medicine on advanced primary liver cancer.

The curative effective research of Chinese herbal medicine on advanced primary liver cancer.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15007349
Enrollment
Unknown
Registered
2015-10-26
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary carcinoma of liver

Interventions

The treatment group:Ganji granule and basic therapy
The control group:basic therapy

Sponsors

Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Conforms to the diagnostic standard of primary liver cancer (the diagnosis and treatment specification of primary liver cancer, 2011 edition),which is caused hepatitis B virus and in the B/C phase accroding to Barcelona clinic liver cancer staging, 2010 eidtion; 2. It has been 6 months since patients acceptting surgical treatment (surgery, intervention or radiofrequency ablation); 3. Age ranges from 18 to 65 years,any gender; 4. Be willing to accept traditional Chinese medicine or traditional Chinese and western medicine treatment; 5. Must sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Metastatic liver cancer patients, or patients complicated with other tumors; 2. Patients with BCLC stage for D, or associated with refractory ascites, hepatic encephalopathy,liver failure or portal vein embolization; 3. Patients with severe primary disease of heart,kidney,lung,endocrine,metabolism,blood or gastrointestinal tract;Or psychiatric patients; 4. The disabled, pregnant women or nursing mothers; 5. People with allergic physique or multiple drug allergy patients; 6. Patients using molecular targeted anti-tumor drugs(Sophie).

Design outcomes

Primary

MeasureTime frame
TCM syndromes;Liver Function;HBV-M;HBV-DNA;AFP;KPS;EORTCQLQ-C30;performance status;Pathological diagnosis;iconographic diagnosis;

Countries

China

Contacts

Public ContactSun Xuehua
susan_sxh@sina.com+86 13585769286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026